The University of Southampton
University of Southampton Institutional Repository

Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes

Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes
Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes

An effective human immunodeficiency virus 1 (HIV-1) vaccine will most likely have to elicit broadly neutralizing antibodies (bNAbs) to overcome the sequence diversity of the envelope glycoprotein (Env). So far, stabilized versions of Env, such as SOSIP trimers, have been able to induce neutralizing antibody (NAb) responses, but those responses are mainly strain-specific. Here we attempted to broaden NAb responses by using a multivalent vaccine and applying a number of design improvements. First, we used highly stabilized SOSIP.v9 trimers. Second, we removed any holes in the glycan shields and optimized glycan occupancy to avoid strain-specific glycan hole responses. Third, we selected five sequences from the same clade (B), as we observed previously that combining Env trimers from clade A, B and C did not improve cross-reactive responses, as they might have been too diverse. Fourth, to improve antibody (Ab) responses, the Env trimers were displayed on two-component I53-50 nanoparticles (NPs). Fifth, to favor activation of cross-reactive B cells, the five Env trimers were co-displayed on mosaic NPs. Sixth, we immunized rabbits four times with long intervals between vaccinations. These efforts led to the induction of cross-reactive B cells and cross-reactive binding Ab responses, but we only sporadically detected cross-neutralizing responses. We conclude that stabilized HIV-1 Env trimers that are not modified specifically for priming naive B cells are unable to elicit strong bNAb responses, and infer that sequential immunization regimens, most likely starting with specific germline-targeting immunogens, will be necessary to overcome Env's defenses against the induction of NAbs. The antigens described here could be excellent boosting immunogens in a sequential immunization regimen, as responses to bNAb epitopes were induced.

HIV-1/immunology, HIV Antibodies/immunology, Animals, env Gene Products, Human Immunodeficiency Virus/immunology, AIDS Vaccines/immunology, Humans, Epitopes/immunology, Antibodies, Neutralizing/immunology, Nanoparticles, Rabbits, HIV Infections/immunology, Broadly Neutralizing Antibodies/immunology, Antibody Formation/immunology
1553-7366
Brinkkemper, Mitch
e7da2264-2df6-4eb8-b8cb-f8701adc2771
Kerster, Gius
9de2fe87-c29e-46c4-8e2b-6ffd3769665a
Brouwer, Philip J.M.
9a3ab106-b09e-4f03-a4ff-bb9dcf99eeed
Tran, Andy S.
a6433714-3130-4c94-875b-3ce299a897b0
Torres, Jonathan L.
8e9a3e7b-a841-4748-927b-967ac8135774
Ettema, Roos A.
04cc9e9c-5d82-41dc-95cc-a3a30b40a95f
Nijhuis, Haye
fe6a15cb-1dad-4201-8110-ea177faf723b
Allen, Joel D.
c873d886-2a66-475b-ae04-57a10b37e716
Zhu, Wenwen
83e996dd-ae44-4066-9d76-6622e1a2e1a2
Gao, Hongmei
4dbf6f50-fb2e-4f56-99f4-23e0fe8b2d69
Lee, Wen-Hsin
a30e425f-7907-4f8c-b1e0-682dec238fae
Bijl, Tom P.L.
7c64fdad-a591-419c-9d15-394a6561fd7e
Snitselaar, Jonne L.
1de6b1ee-185f-4683-ba9c-b1fc8f5e2443
Burger, Judith A.
a72f1372-e14b-410a-980d-526e641ed3dc
Bontjer, Ilja
5c8af5ca-c330-47f2-a0c4-bda0dfdc2a58
Olijhoek, Wouter
69ac47b9-5e70-4763-b9c3-86b93f6d6475
Ravichandran, Rashmi
81fdf5de-9e41-4a3e-b6bf-d8d90a4dda0e
van Breemen, Marielle J.
7ebee565-7ea1-42c8-8e5a-591bd5f2f397
Del Moral-Sánchez, Iván
d81d4565-e24f-4c80-ae34-73812e74b7d4
Derking, Ronald
66536ca3-069b-448e-9703-42202044a04b
Sliepen, Kwinten
d2551fe9-7d04-459e-85b5-29fc4b35317a
Ozorowski, Gabriel
9d448a80-7310-4b30-ba44-ee8b18222a02
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
Montefiori, David C.
e1f1e5f0-7bed-4994-81e2-7f1e0ff5663b
Claireaux, Mathieu
1fe67610-b7f0-4a30-9307-12bc53b37f52
Ward, Andrew B.
78ce5b6a-b852-4ee4-a950-f7ff7b183d83
van Gils, Marit J.
f2e1e7f1-36a1-4270-8509-d17a10ddb9a6
King, Neil P.
19437abf-1af8-4243-975f-0f4cbfeda355
Sanders, Rogier W.
d3b67c2c-c725-42e7-b972-50b30be67c74
et al.
Brinkkemper, Mitch
e7da2264-2df6-4eb8-b8cb-f8701adc2771
Kerster, Gius
9de2fe87-c29e-46c4-8e2b-6ffd3769665a
Brouwer, Philip J.M.
9a3ab106-b09e-4f03-a4ff-bb9dcf99eeed
Tran, Andy S.
a6433714-3130-4c94-875b-3ce299a897b0
Torres, Jonathan L.
8e9a3e7b-a841-4748-927b-967ac8135774
Ettema, Roos A.
04cc9e9c-5d82-41dc-95cc-a3a30b40a95f
Nijhuis, Haye
fe6a15cb-1dad-4201-8110-ea177faf723b
Allen, Joel D.
c873d886-2a66-475b-ae04-57a10b37e716
Zhu, Wenwen
83e996dd-ae44-4066-9d76-6622e1a2e1a2
Gao, Hongmei
4dbf6f50-fb2e-4f56-99f4-23e0fe8b2d69
Lee, Wen-Hsin
a30e425f-7907-4f8c-b1e0-682dec238fae
Bijl, Tom P.L.
7c64fdad-a591-419c-9d15-394a6561fd7e
Snitselaar, Jonne L.
1de6b1ee-185f-4683-ba9c-b1fc8f5e2443
Burger, Judith A.
a72f1372-e14b-410a-980d-526e641ed3dc
Bontjer, Ilja
5c8af5ca-c330-47f2-a0c4-bda0dfdc2a58
Olijhoek, Wouter
69ac47b9-5e70-4763-b9c3-86b93f6d6475
Ravichandran, Rashmi
81fdf5de-9e41-4a3e-b6bf-d8d90a4dda0e
van Breemen, Marielle J.
7ebee565-7ea1-42c8-8e5a-591bd5f2f397
Del Moral-Sánchez, Iván
d81d4565-e24f-4c80-ae34-73812e74b7d4
Derking, Ronald
66536ca3-069b-448e-9703-42202044a04b
Sliepen, Kwinten
d2551fe9-7d04-459e-85b5-29fc4b35317a
Ozorowski, Gabriel
9d448a80-7310-4b30-ba44-ee8b18222a02
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
Montefiori, David C.
e1f1e5f0-7bed-4994-81e2-7f1e0ff5663b
Claireaux, Mathieu
1fe67610-b7f0-4a30-9307-12bc53b37f52
Ward, Andrew B.
78ce5b6a-b852-4ee4-a950-f7ff7b183d83
van Gils, Marit J.
f2e1e7f1-36a1-4270-8509-d17a10ddb9a6
King, Neil P.
19437abf-1af8-4243-975f-0f4cbfeda355
Sanders, Rogier W.
d3b67c2c-c725-42e7-b972-50b30be67c74

Brinkkemper, Mitch, Kerster, Gius and Brouwer, Philip J.M. , et al. (2024) Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes. PLoS Pathogens, 20 (10), [e1012558]. (doi:10.1371/journal.ppat.1012558).

Record type: Article

Abstract

An effective human immunodeficiency virus 1 (HIV-1) vaccine will most likely have to elicit broadly neutralizing antibodies (bNAbs) to overcome the sequence diversity of the envelope glycoprotein (Env). So far, stabilized versions of Env, such as SOSIP trimers, have been able to induce neutralizing antibody (NAb) responses, but those responses are mainly strain-specific. Here we attempted to broaden NAb responses by using a multivalent vaccine and applying a number of design improvements. First, we used highly stabilized SOSIP.v9 trimers. Second, we removed any holes in the glycan shields and optimized glycan occupancy to avoid strain-specific glycan hole responses. Third, we selected five sequences from the same clade (B), as we observed previously that combining Env trimers from clade A, B and C did not improve cross-reactive responses, as they might have been too diverse. Fourth, to improve antibody (Ab) responses, the Env trimers were displayed on two-component I53-50 nanoparticles (NPs). Fifth, to favor activation of cross-reactive B cells, the five Env trimers were co-displayed on mosaic NPs. Sixth, we immunized rabbits four times with long intervals between vaccinations. These efforts led to the induction of cross-reactive B cells and cross-reactive binding Ab responses, but we only sporadically detected cross-neutralizing responses. We conclude that stabilized HIV-1 Env trimers that are not modified specifically for priming naive B cells are unable to elicit strong bNAb responses, and infer that sequential immunization regimens, most likely starting with specific germline-targeting immunogens, will be necessary to overcome Env's defenses against the induction of NAbs. The antigens described here could be excellent boosting immunogens in a sequential immunization regimen, as responses to bNAb epitopes were induced.

Text
journal.ppat.1012558 (1) - Version of Record
Available under License Creative Commons Attribution.
Download (3MB)

More information

Accepted/In Press date: 2 September 2024
e-pub ahead of print date: 3 October 2024
Keywords: HIV-1/immunology, HIV Antibodies/immunology, Animals, env Gene Products, Human Immunodeficiency Virus/immunology, AIDS Vaccines/immunology, Humans, Epitopes/immunology, Antibodies, Neutralizing/immunology, Nanoparticles, Rabbits, HIV Infections/immunology, Broadly Neutralizing Antibodies/immunology, Antibody Formation/immunology

Identifiers

Local EPrints ID: 498518
URI: http://eprints.soton.ac.uk/id/eprint/498518
ISSN: 1553-7366
PURE UUID: 8dd7d4f8-51f5-4829-9764-111cf95d260c
ORCID for Max Crispin: ORCID iD orcid.org/0000-0002-1072-2694

Catalogue record

Date deposited: 20 Feb 2025 17:43
Last modified: 22 Aug 2025 02:19

Export record

Altmetrics

Contributors

Author: Mitch Brinkkemper
Author: Gius Kerster
Author: Philip J.M. Brouwer
Author: Andy S. Tran
Author: Jonathan L. Torres
Author: Roos A. Ettema
Author: Haye Nijhuis
Author: Joel D. Allen
Author: Wenwen Zhu
Author: Hongmei Gao
Author: Wen-Hsin Lee
Author: Tom P.L. Bijl
Author: Jonne L. Snitselaar
Author: Judith A. Burger
Author: Ilja Bontjer
Author: Wouter Olijhoek
Author: Rashmi Ravichandran
Author: Marielle J. van Breemen
Author: Iván Del Moral-Sánchez
Author: Ronald Derking
Author: Kwinten Sliepen
Author: Gabriel Ozorowski
Author: Max Crispin ORCID iD
Author: David C. Montefiori
Author: Mathieu Claireaux
Author: Andrew B. Ward
Author: Marit J. van Gils
Author: Neil P. King
Author: Rogier W. Sanders
Corporate Author: et al.

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×